Does Restaurant brands international (parent entity of burger King brand) owns any stake in restaurant brands Asia?

Same dates considered similar to Microcap
12 months date :19/05/2023
06 months date: 17/11/2023

Exciting News Alert from Shilpa Medicare Limited!

We are thrilled to announce a significant milestone at Shilpa Medicare Limited!

“ Clinical Trial Announcement for SML 007”

Our groundbreaking drug, “SML-007”, designed to combat non-alcoholic fatty liver disease (NAFLD), has successfully completed its early clinical development phase and is now in the midst of an ongoing Phase 3 clinical trial.

What makes “SML-007” stand out? It’s an orally administered medication with revolutionary benefits surpassing conventional bile acid drugs. By reshaping bile acid synthesis and stimulating liver FXR signaling, it offers a promising pathway for NAFLD treatment. Moreover, its action through the adiponectin receptor pathway showcases unparalleled potential in combating inflammation and fibrosis.

Why is this significant? NAFLD affects a staggering 25% of the global population, with 14% progressing to the more severe non-alcoholic steatohepatitis (NASH), posing serious risks of liver fibrosis, cirrhosis, or Liver cancer.

Our dedication to advancing healthcare through innovation is evident in the development of SML-007, which holds the potential to revolutionize the treatment landscape for liver disease

Q4 Con-call Highlights (FY24)

• The health insurance sector in India is growing, supported by government initiatives like the aim to enable insurance for all by 2047. This will have a positive impact on the insurance industry and TPAs like Medi Assist.
• Medi Assist’s total premiums under management grew by 30.7% YoY to Rs. 19,550 crores as of 31st March 2024. The group segment grew 30.4% and retail segment grew 33.2%.
• Medi Assist’s share of the industry’s health insurance premiums increased by 86 bps to 19.6%. For group business, it was 30.4% market share (up 299 bps) and for retail it was 5.5% (up 50 bps).
• Key financial highlights:
  • Q4 FY24 total income grew 32.9% YoY
  • FY24 total income grew 25.8% YoY
  • FY24 operating revenue grew 25.7% YoY
  • FY24 profit after tax (excl. exceptional item) grew 22.6% YoY to Rs. 92.3 crores
• The company maintained a high group policy retention rate of 94.7% in FY24.
• It processed 3.6 million outpatient claims in FY24, improving cash utilization.
• Medi Assist aims to integrate recent acquisitions and achieve pre-acquisition margins of 23-24% in the next few quarters.
• The company has a strong cash position of Rs. 245 crores despite acquisitions worth Rs. 135 crores during the year.